Search Results - efrosini+kokkoli

5 Results

Sort By:

A Thermosensitive and Biodegradable Hydrogel as a Delivery System for the Local and Controlled Release of a Blood Pressure Drug (Valsartan) Combined with Senolytics (Dasatinib and Quercetin) to Treat Chronic Diabetic Wounds

JHU Ref #: C16199 Value Proposition:Provides a slow, sustained release of a combination therapy to reverse cellular senescence and enhance collagen production in proliferating and senescent primary dermal fibroblasts.Utilizes a thermosensitive and biodegradable hydrogel for sustained release of nanoparticles and drugs. Requires fewer applications compared...

Published: 9/27/2024 | Inventor(s): Efrosini Kokkoli, Peter Abadir, Jeremy Walston, Paul Kuhn

Keywords(s):

Category(s):

Hydrogel-Nanoparticle System for Localized Therapeutic Cocktail Delivery in Invasive Ductal Carcinoma (IDC)

Unmet Need: Systemic delivery of drugs often leads to faster clearance, off-target effects, and system-wide unintended toxicity. Current therapeutics designed to specifically target invasive ductal carcinoma (IDC) have a narrow therapeutic index, lack predictive biomarkers, and have serious side effects due to off-target toxicity. This lack of efficacy...

Published: 9/27/2024 | Inventor(s): Efrosini Kokkoli, Denis Wirtz, Gabriella Russo, Paul Kuhn

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology > Breast Cancer

Organo-phosphate Modified Metal Organic Frameworks and Applications

Marketing Summary Draft #C17480 Organo-phosphate Modified Metal Organic Frameworks and ApplicationsInventors: Michael Tsapatsis, Efrosini Kokkoli, Danyu WangUnmet NeedThere is a continuously growing need for new and better asymmetric catalysts, as is evidenced by the fact that the 2021 Nobel Prize in Chemistry went to two scientists for development...

Published: 9/27/2024 | Inventor(s): Michael Tsapatsis, Efrosini Kokkoli, Danyu Wang

Keywords(s):

Category(s):

ssDNA Nanotubes Targeting Brain Tumors and Other Cancers Selectively

Unmet NeedA large number of cancers, including glioblastoma (GBM), lack effective treatment due to inaccessibility of the primary tumor to pharmaceutical interventions. GBM is highly malignant, leading to 5-year survival rates below 10%. The inability to treat GBM tumors effectively is largely due to the blood brain barrier (BBB). Common approaches...

Published: 9/27/2024 | Inventor(s): Efrosini Kokkoli, Zachary Schneiderman

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Brain Cancer, Technology Classifications > Therapeutic Modalities

Targeted Liposomes Encapsulating miR-603 Complexes

Unmet Need: Glioblastoma (GBM) is the most common malignant brain tumor in adults, affecting 17K patients in the US annually. GBM stem cells underlie GBM recurrence, leading to treatment resistance and poor patient outcomes. Standard treatments remove the primary tumor cells but leave space for GBM stem cells to cause tumorigenesis. There is a need...

Published: 9/27/2024 | Inventor(s): Efrosini Kokkoli, Clark Chen, Zachary Schneiderman

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology > Glioblastoma, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities